The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis

Ana Carolina Japur de Sá Rosa e Silva; Júlio Cesar Rosa e Silva; Antônio Alberto Nogueira; Carlos Alberto Petta; Maurício Simões Abrão; Rui Alberto Ferriani

doi:10.1016/j.fertnstert.2006.02.082

The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis

Fertil Steril. 2006 Sep;86(3):742-4. doi: 10.1016/j.fertnstert.2006.02.082. Epub 2006 Jun 19.

Authors

Ana Carolina Japur de Sá Rosa e Silva¹, Júlio Cesar Rosa e Silva, Antônio Alberto Nogueira, Carlos Alberto Petta, Maurício Simões Abrão, Rui Alberto Ferriani

Affiliation

¹ Department of Obstetrics and Gynecology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. anasars@convex.com.br

PMID: 16784745
DOI: 10.1016/j.fertnstert.2006.02.082

Abstract

This study compared the long-term effects of the levonorgestrel-releasing intrauterine device with those of GnRH agonist administration on serum levels of CA-125 in patients with endometriosis. The levonorgestrel-releasing intrauterine device was found to be as efficient as GnRH agonist in reducing CA-125 serum levels.

Publication types

Randomized Controlled Trial

MeSH terms

Adolescent
Adult
CA-125 Antigen / blood*
Contraceptive Agents, Female / administration & dosage
Endometriosis / blood*
Endometriosis / drug therapy*
Equipment Failure Analysis
Female
Humans
Intrauterine Devices, Medicated*
Levonorgestrel / administration & dosage*
Treatment Outcome

Substances

CA-125 Antigen
Contraceptive Agents, Female
Levonorgestrel